The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
 
Seth Andrew Wander
Consulting or Advisory Role - Biovica; Foundation Medicine; Hologic; Lilly; Pfizer; Puma Biotechnology; Veracyte
Speakers' Bureau - Guardant Health; Lilly
Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics
 
Caroline M. Weipert
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Jiemin Liao
Employment - Guardant Health; Roche/Genentech (I)
Stock and Other Ownership Interests - Guardant Health; Roche/Genentech (I)
Research Funding - Guardant Health
 
Anton Safonov
No Relationships to Disclose
 
Nicole Zhang
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Patents, Royalties, Other Intellectual Property - RWE selection patent application pending
Travel, Accommodations, Expenses - Guardant Health
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Guardant Health; Inivata; Natera; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); AstraZeneca (Inst); bioTheranostics (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)